mednous managing european medical innovation leyden labs

May 11, 2021

MedNous addressing multiple uses for Leyden Labs' nasal sprays

Last month, our CEO Koenraad Wiedhaup spoke with co-founder and editor of MedNous, Victoria English, about Leyden Labs. They discussed the development of our platform and portfolio of prophylactic nasal sprays that should protect people from infection with respiratory viruses, such as influenza and coronaviruses.

English also discusses how Leyden Labs' intranasal products could play an important role in preventing and managing future pandemics. Firstly, when a spray like this would be available from the start of a viral outbreak, people could protect themselves until efficacious vaccines are widely distributed. Additionally, at later stages of a pandemic when vaccines may have been developed, people may still be seeking additional protection. For instance, people with compromised immune systems for whom vaccines may not as effective can benefit from additional protection from Leyden Labs' nasal spray on top of the vaccine. 

To read the full article, click here.  

Published in the April 2021 edition of MedNous, a publication of Evernow Publishing Ltd.

LL-Blue

OUR NEW APPROACH  |  OUR TEAM  |  JOIN OUR MISSION   |  NEWS  |  CAREERS  

Contact

Media inquiries

Stay updated

Leyden Laboratories B.V.

Leiden Laboratory
J.H. Oortweg 21
2333 CH Leiden
The Netherlands


Leyden Laboratories Co.

Boston Laboratory
191 Dexter Avenue
Watertown
MA 02472
United States


Leyden Labs S.L.

Granada Office
Avda. del Conocimiento 41.A214
Centro de Empresas
Parque Tecnológico de la Salud
18016 Granada
Spain


© Leyden Labs, 2021  |  Privacy Policy  |  Design by Ape to Zebra

Back to top Arrow